socalTECH

MAY 20, 2016

San Diego-based Avalon Ventures , and COI Pharmaceuticals , the company established by Avalon to help form new biotech companies, said today that the first two companies that it has formed with GlaxoSmithKline have met their first milestones, and that it has spun up a new company with GSK as part of their collaboration.

Avalon 113

Avalon Company Companies San Diego 113

socalTECH

JUNE 15, 2015

San Diego-based Avalon Ventures said this morning that it has launched and funded three, new companies as part of its deal with GSK. Avalon Venturs said that Adrenergics , CadheRx Therapeutics , and Calporta Therapeutics have all received $10M in Series A funding, and will receive R&D support from Avalon Ventures and GSK.

Avalon 100

Avalon San Diego Startup Funding 100

Xconomy

SEPTEMBER 11, 2019

GlaxoSmithKline is acquiring a startup it helped launch in 2013 as part of an alliance with life sciences venture capital firm Avalon Ventures. Avalon said Tuesday that GSK (NYSE: GSK ) has agreed to buy the company, Sitari Pharmaceuticals, which has been developing a treatment for celiac disease.

Avalon 56

Avalon Invest Southern California Develop 56

socalTECH

JULY 17, 2014

The latest venture capital totals from the PricewaterhouseCoopers/National Venture Capital Association''s MoneyTree Report was released this evening, tallying up $761.12M in investments in Q2 of 2014 in Southern California, up from Q2 of 2013, when $616.83M was invested in the region.

Southern California 240

Southern California El Segundo Culver City Orange County 240

socalTECH

MARCH 29, 2021

San Diego-based Fortis Therapeutics, a biotechnology startup developing treatments for late-stage prostate cancer and multiple myeloma, has raised $40M in a Series A financing, the company said on Monday.

Avalon 113

Avalon San Diego Research Funding 113

socalTECH

DECEMBER 4, 2015

The funding was led by Avalon Ventures and TPG Biotech, and also included Correlation Ventures and Osage University Partners. The startup said it is developing novel drugs based on the anti-cancer activity of metformin and designed to reduce cancer energy production to treat a range of cancer types.

UCLA 100

UCLA Avalon San Diego Los Angeles 100

Xconomy

AUGUST 17, 2016

It was joined by two other new backers, Ervington Investments and Alexandria Venture Investments, and previous investors WuXi Healthcare Ventures, Bregua Corp., and San Diego’s Avalon Ventures. Inbio Ventures, a venture capital management company, represented Pharmstandard in the deal.

Avalon 40

Avalon San Diego Study Invest 40